July 17, 2026
RSI Oversold in Review: The Late-June Cohort
A data review of the late-June RSI Oversold list: what happened to BABA, MSTR, PDD and T in the three weeks after they appeared on the screener.
In late June the market handed the RSI Oversold screener one of its busiest stretches of the year. The list dated June 21 held 134 names. By June 25 it had swollen to 145. A week later, on July 1, it was back down to 65. That expansion and contraction is itself a data point: a broad washout happened in the last week of June, and it reset quickly.
This article looks at what happened next for four of the most liquid names that appeared in that window: Alibaba (BABA), MicroStrategy (MSTR), PDD Holdings (PDD) and AT&T (T). Everything below uses closing prices from our own candle data, measured from the first close after each name appeared on the list through July 16.
The numbers, three weeks on
| Symbol | On the list | First close after | Close Jul 16 | Change | Worst close in between |
|---|---|---|---|---|---|
| PDD | Jun 25 | $73.30 | $86.68 | +18.3% | never below entry |
| BABA | Jun 21 to Jun 30 | $104.97 | $117.49 | +11.9% | $94.81 (-9.7%) |
| MSTR | Jun 25 and Jun 28 | $85.33 | $94.03 | +10.2% | $82.31 (-3.5%) |
| T | Jul 1 | $20.48 | $21.98 | +7.3% | never below entry |
PDD is the cleanest case in the cohort. It appeared once, on the June 25 list, closed at $73.30 that day and never printed a lower close afterwards. Three weeks later it stood at $86.68, a gain of 18.3%. AT&T, the defensive name in the group, joined the list on July 1 at $20.48 and ground higher in almost a straight line to $21.98.
The uncomfortable part: BABA went lower first
Alibaba is the more instructive story. It appeared on the oversold list on June 21 and stayed there for eight consecutive list dates, through June 30. Anyone who treated the first appearance as a finished bottom watched the stock fall another 9.7% to a closing low of $94.81 on June 26 before it turned. From that low the recovery was fast, and by July 16 BABA had reached $117.49, up 11.9% from its first post-listing close. But the sequence matters: oversold readings can persist, and the screener kept re-listing the stock precisely because the condition kept being true.
MicroStrategy showed a milder version of the same pattern. Listed on June 25 at a close of $85.33, it slipped to $82.31 the next day before rallying to a closing peak of $100.77 on July 2, an 18.1% swing off the listing close in five sessions. It then gave part of that back and sat at $94.03 on July 16.
What an oversold list is actually telling you
The RSI Oversold screener does one narrow job: it surfaces stocks whose 14-day RSI has dropped below a threshold that historically marks stretched selling. It says nothing about why the selling happened, and it makes no claim that a bounce is due. The late-June cohort illustrates both sides of that honestly. Four liquid names recovered between 7% and 18% within three weeks, while the list size itself (134, then 145, then 65) shows how quickly the condition washed through the broader market.
The practical use of the data is context, not prediction. When the list triples in size, something market-wide is happening. When a single name sits on the list for eight straight sessions, the selling is persistent rather than a one-day flush. Both facts are visible in the screener history before any price recovery confirms them.
Reproducing this review
Every figure above comes from data you can see on the platform: the daily screener lists and the closing prices on each symbol page. If you want to run the same review for the current list, open the RSI Oversold screener, note the names and dates, and check back in a few weeks. The glossary explains the RSI calculation itself if the mechanics are new to you.
Related Resources
- RSI Oversold Screener for the current list.
- How the RSI Oversold screener works for the methodology.
- Glossary for the RSI definition and related terms.
This article is a retrospective review of historical data for educational purposes only. It is not investment advice, no outcome shown here is a promise of future results, and screener appearances are data points, not recommendations.